The CRA Who Kept the Finding to Herself
You are the Clinical Operations Lead for a Phase II oncology study at 14 sites. A monitoring report from Site 07 shows a routine visit with no major findings, but a week later the site coordinator emails you directly: she says the CRA "saw the temperature excursions in the freezer log but told me not to worry because the drug looked fine." You pull the source documents. There are 11 excursions over four months on a biologic IP stored at -20°C; the protocol specifies -20°C ± 5°C. Six excursions exceeded -15°C for 2-9 hours. Three enrolled patients received doses from those lots. The CRA's report contains no mention of the excursions. The CRA has been with the company for nine years and monitors five of your 14 sites. The site has already shipped the affected kits back to the depot, which quarantined them without notifying you.
1. What is your immediate action plan, and who must be notified?
Read the worked answer
Immediate (within 24-48h):
- Do not confront the CRA in writing yet - but pull her other four sites' monitoring reports and any deviation logs for the same period. If this is a pattern, the scope is far larger than one site.
- Escalate internally today: Medical Monitor, QA, and Pharmacovigilance. This is a potential IP integrity failure affecting subject safety, not a documentation issue.
- Contact the depot in writing to preserve the quarantined kits, lot numbers, and excursion records - chain of custody matters for the investigation.
- Notify the sponsor's Qualified Person / drug supply lead so an impact assessment on the affected lots can begin (potency/stability data, whether the biologic degrades at -15°C).
- Assess the three patients: Medical Monitor reviews their response and any AEs. Depending on the product, this may meet the definition of a serious breach or an incident requiring reporting.
Regulatory judgment: The excursion plus the CRA's failure to report it is a quality event. Whether it becomes a reportable event depends on whether it materially affected subject safety or data reliability - that determination belongs to the Medical Monitor and QA, documented, not to you alone. Do not pre-decide it.
Do not tell the coordinator to stop emailing you - she is a protected reporter and the source of your information.
2. How do you handle the CRA, and what does this tell you about your monitoring oversight system?
Read the worked answer
The CRA: This is not a coaching conversation. A monitor who observes an excursion and affirmatively tells site staff to disregard it has (a) failed to document a finding, (b) given advice outside her remit, and (c) potentially compromised subject safety. That is a performance and integrity matter for HR/QA, not a training gap. Remove her from this study pending review - not punitively in a way that looks like retaliation, but because she is now a witness in an investigation she would otherwise be documenting.
The system: The deeper failure is that a CRA could suppress a finding and no one would catch it for a week. Ask:
- Do your monitoring reports have a mandatory field for IP storage deviations that cannot be left blank?
- Is there a second-line review of reports for sites with high enrollment or high-risk products?
- Did the site coordinator have an independent route to raise concerns? (She used it - but only because she happened to trust you.)
- Why did the depot quarantine kits without notifying the sponsor? That's a supply-chain communication gap.
CAPA: Root cause is likely a culture where "no major findings" reports are rewarded and a monitor with nine years' tenure is not challenged. Fix the reporting template, add QA sampling of reports, and confirm the depot's escalation path in writing.